Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ampreloxetine
- Development stage
- Discontinued
- Lead developer
- Theravance Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ampreloxetine (TD-9855) is an investigational, potent, and long-acting norepinephrine reuptake inhibitor (NRI) being developed by Theravance Biopharma. It is designed for the once-daily treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). By selectively inhibiting the norepinephrine transporter (NET), ampreloxetine increases the levels of norepinephrine in the synaptic cleft, which helps to maintain blood pressure and reduce symptoms like dizziness and syncope when standing. The drug is currently being evaluated in the Phase 3 CYPRESS trial, following a strategic funding agreement with Royalty Pharma to support its development in the MSA subpopulation.
- Other names
- ampreloxetine
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on ampreloxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ampreloxetine.